ERBB2 and gastroesophageal junction adenocarcinoma: Trastuzumab (Herceptin®®, Ogivri®®, Herzuma®®), an anti-HER2 monoclonal Ab, was originally developed for HER2+ metastatic breast cancer but has subsequently been approved for gastric adenocarcinoma and gastroesophageal junction adenocarcinoma.